Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Top Cited Papers
Open Access
- 22 January 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1), 5
- https://doi.org/10.1186/s40425-018-0315-0
Abstract
Background: An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role with contemporary immune checkpoint blockade (ICB) is unknown. We investigated the utility of NLR in metastatic renal cell carcinoma (mRCC) patients treated with PD-1/PD-L1 ICB. Methods: We examined NLR at baseline and 6 (+/- 2) weeks later in 142 patients treated between 2009 and 2017 at Dana-Farber Cancer Institute (Boston, USA). Landmark analysis at 6 weeks was conducted to explore the prognostic value of relative NLR change on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Cox and logistic regression models allowed for adjustment of line of therapy, number of IMDC risk factors, histology and baseline NLR. Results: Median follow up was 16.6 months (range: 0.7-67.8). Median duration on therapy was 5.1 months (= 25% from baseline to 6 weeks after ICB therapy was associated with reduced ORR and an independent prognostic factor for PFS (p < 0.001) and OS (p = 0.004), whereas a decrease in NLR by >= 25% was associated with improved outcomes. Conclusions: Early decline and NLR at 6 weeks are associated with significantly improved outcomes in mRCC patients treated with ICB. The prognostic value of the readily-available NLR warrants larger, prospective validation.Funding Information
- Foundation for the National Institutes of Health (Kidney Spore)
This publication has 30 references indexed in Scilit:
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Followup of Neutrophil-to-Lymphocyte Ratio and Recurrence of Clear Cell Renal Cell CarcinomaJournal of Urology, 2011
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Cancer-related inflammationNature, 2008
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based ImmunotherapyClinical Cancer Research, 2004
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002